Israel is one of the most consequential cannabis markets in the world relative to its size — but "size" here needs unpacking, because the legal market is only a sliver of actual consumption. This guide lays out the numbers and what they mean.
This guide is informational and is not investment or medical advice. Market figures are estimates and vary by source.
The headline figure
By revenue, the Israeli medical cannabis market is projected at roughly US$372 million in 2025 (Statista) — a substantial figure for a country of about 9.8 million people, and a reflection of one of the largest per-capita licensed-patient populations anywhere. Estimates differ (some peg the market lower), as is normal for a sector where much activity is informal, but the order of magnitude is a few hundred million dollars.
The number that really matters: legal vs illicit
The single most important fact about market size in Israel is the gap between legal and illicit consumption. Industry estimates put illicit users in the low millions — around 2.4 million estimated illicit users against roughly 132,800 legal medical patients in 2025 (GrowerIQ). In other words, the regulated channel serves well under 10% of actual cannabis consumption in the country.
That gap is the entire long-term growth thesis for licensed operators: the addressable market isn't really 132,800 patients, it's the millions of people currently served by the illicit market. Converting even a fraction of them into legal patients would multiply the regulated market's size.
A medical-only market
It is worth being clear about what this market is: strictly medical. There is no legal recreational market in Israel (see is cannabis legal in Israel?), so every shekel of regulated revenue comes through the Ministry of Health licence-and-pharmacy system. That ceiling — medical-only — is part of why the legal market stays small relative to consumption.
What constrains it
Three things cap the legal market's size in practice: it is medical-only; the patient base has stopped growing and even declined since the 2024 reform; and pricing sits outside the subsidised health basket, so cost deters some patients. Together these explain why a country with world-leading research and high per-capita patient numbers still has a legal market measured in the hundreds of millions, not billions.
The takeaway
Israel's legal cannabis market is meaningful but modest in absolute terms, and dwarfed by illicit consumption. The bull case is conversion of that illicit demand; the bear case is that a medical-only framework, a plateauing patient base and policy friction keep the legal market boxed in. For the demand side, see Israel's cannabis patient numbers; for the supply side, Israel's cannabis imports and supply; and for the full picture, our Market hub.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Market.